Nathaniel M Lewis,Elizabeth J Harker,Lauren B Grant,Yuwei Zhu,Carlos G Grijalva,James D Chappell,Jillian P Rhoads,Adrienne Baughman,Jonathan D Casey,Paul W Blair,Ian D Jones,Cassandra A Johnson,Adam S Lauring,Manju Gaglani,Shekhar Ghamande,Cristie Columbus,Jay S Steingrub,Nathan I Shapiro,Abhijit Duggal,Laurence W Busse,Jamie Felzer,Matthew E Prekker,Ithan D Peltan,Samuel M Brown,David N Hager,Michelle N Gong,Amira Mohamed,Matthew C Exline,Akram Khan,Catherine L Hough,Jennifer G Wilson,Jarrod Mosier,Nida Qadir,Steven Y Chang,Adit A Ginde,Amanda Martinez,Nicholas M Mohr,Christopher Mallow,Estelle S Harris,Nicholas J Johnson,Vasisht Srinivasan,Kevin W Gibbs,Jennie H Kwon,Ivana A Vaughn,Mayur Ramesh,Basmah Safdar,Anirudh Goyal,Lauren E DeLamielleure,Jennifer DeCuir,Diya Surie,Fatimah S Dawood,Mark W Tenforde,Timothy M Uyeki,Shikha Garg,Sascha Ellington,Wesley H Self,for the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network,Manjusha Gaglani,Tresa McNeal,Shekhar Ghamande Nicole Calhoun,Kempapura Murthy,Joselyn Cravens,Judy Herrick,Amanda McKillop,Eric Hoffman,Ashley Graves,Martha Zayed,Michael Smith,Manjusha Gaglani,Cristie Columbus,Ashley Bychkowski,Symone Dunkley,Tammy Fisher,Therissa Grefsrud,Mariana Hurutado-Rodriguez,Gabriela Perez,Laurence Busse,Caitlin ten Lohuis,Jamie Felzer,Matthew Prekker,Audrey Hendrickson,Anne Frosch,Leyla Taghizadeh,Kowsar Hurreh,Mary O'Rourke,Laurynn Giles,Ivana A Vaughn,Mayur Ramesh,Lois E Lamerato,Khaled Almawri,Ishraaq Atkins,Jaleesa Clark,Jean Ashley Lava,Catherine McKeon,Zina Pinderi,Melissa Resk,Sindhuja Koneru,Rachna Jayaprakash,Shruti Tirumala,Katrina Williams,Ithan Peltan,Jenna Lumpkin,Shandi Poulson,Joslyn Bassett,Vineela Thumma,David N Hager,Harith Ali,Safa Saeed Richard,Nicholas Mohr,Anne Zepeski,Paul Nassar,Jacob Hampton,Cathy Fairfield,Heath Gibbs,Courtney Feitsam,Ike Appleton,Michelle Ng Gong,Amira Mohamed,Luke Andrea,Matthew Exline,Sarah Karow,Gabrielle Swoope,Madison So,Manisha Pathak,David Smith,Reece Wilson,Zachery Lewald,Connor Snyder,Maryiam Khan,Brooke Lee,Amanie Rasul,Akram Khan,Adrian Hernandez-Frausto,Edvinas Pocius,Emily Tribbett,Genesis Briceno,Jose Pena,Sarah Pellicer,Raju Reddy,Gopal Allada,Jennifer Wilson,Alexandra June Gordon,Cynthia Perez,Lilian Lau,Samantha Ferguson,Vanessa Pitre,Grace Tam,Leonard Basobas,Jarrod Mosier,Karen Lutrick,Cameron Hypes,Beth Salvagio Campbell,Adit Ginde,Amanda Martinez,Aimee Steinwand,Amy Sullivan,Cori Withers,Jacob Rademacher,Rachel Obradovich,Chris Mallow,Carolina Rivas,Nicholas Johnson,Joshua Acidera,Katherine Elkort,Amol Gajendragadkar,Maile McKeown,Wesley H Self,H Keipp Talbot,Carlos Grijalva,Paul W Blair,Ian D Jones,Natasha Halasa,James D Chappell,Kelsey N Womack,Jillian Rhoads,Colleen Ratcliff,Adrienne Baughman,Jakea Johnson,Sydney Swan,Cassandra Johnson,Yuwei Zhu,Todd W Rice,Jonathan D Casey,Yuwei Zhu,Laura L Short,Lauren J Ezzell,Margaret E Whitsett,Rendie E McHenry,Samarian J Hargrave,Jennifer L Luther,Claudia Guevara Pulido,Bryan PM Peterson,Shanice L Cummings,Emma Claire Gauthier,Anna C Jackson,Neekar S Rashid,Marcia Blair,Caroline Rice,Jennie Kwon,Bijal Parikh,David McDonald,Carleigh Samuels,Lucy Vogt,Caroline O'Neil,Alyssa Valencia,Francesca Yerbic,Olivia Arter,Kim Vu,Basmah Safdar,Anirudh Goyal,Lauren DeLamielleure,Michael Kosover

Abstract:Background clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods A multicenter US observational sentinel surveillance network prospectively enrolled adults (aged ≥18 years) hospitalized with laboratory-confirmed influenza at 24 hospitals during October 1, 2022–July 21, 2023. A multivariable proportional odds model was used to compare peak pulmonary disease severity (no oxygen support, standard supplemental oxygen, high-flow oxygen/non-invasive ventilation, invasive mechanical ventilation, or death) after the day of hospital admission among patients starting oseltamivir treatment on the day of admission (early) versus those who did not (late or not treated), adjusting for baseline (admission day) severity, age, sex, site, and vaccination status. Multivariable logistic regression models were used to evaluate the odds of intensive care unit (ICU) admission, acute kidney replacement therapy or vasopressor use, and in-hospital death. Results A total of 840 influenza-positive patients were analyzed, including 415 (49%) who started oseltamivir treatment on the day of admission, and 425 (51%) who did not. Compared with late or not treated patients, those treated early had lower peak pulmonary disease severity (proportional aOR: 0.60, 95% CI: 0.49–0.72), and lower odds of intensive care unit admission (aOR: 0.24, 95% CI: 0.13–0.47), acute kidney replacement therapy or vasopressor use (aOR: 0.40, 95% CI: 0.22–0.67), and in-hospital death (aOR: 0.36, 95% CI: 0.18–0.72). Conclusion Among adults hospitalized with influenza, treatment with oseltamivir on day of hospital admission was associated reduced risk of disease progression, including pulmonary and extrapulmonary organ failure and death.

Early Administration of Oseltamivir Within 48 Hours after Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection.

Influenza A-associated Severe Pneumonia in Hospitalized Patients: Risk Factors and NAI Treatments.

Antiviral Therapy And Outcomes Of Patients With Pneumonia Caused By Influenza A Pandemic (H1n1) Virus

Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.

Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

A Multicentre, Randomized, Controlled Trial of Oseltamivir in the Treatment of Influenza in a High-Risk Chinese Population

A Multicenter Randomized Controlled Study of the Efficacy and Safety of Oseltamivir in the Treatment of Influenza in a High Risk Population

Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study

Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018.

Factors associated with non-prescription of oseltamivir for infant influenza over nine seasons

The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study

Impact of Early Neuraminidase Inhibitor Treatment on Clinical Outcomes in Patients with Influenza B-related Pneumonia: a Multicenter Cohort Study.

Risk factors for hospitalization and pneumonia development of pediatric patients with seasonal influenza during February–April 2023

Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients

Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study

Clinical characteristics of pediatric patients with H1N1 influenza A virus-associated pneumonia

Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza

The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated Pediatric Influenza Patients during Two Influenza Seasons after the COVID-19 Pandemic: The Impact of Comorbidities on Hospitalization for Influenza in Children

Oseltamivir Treatment for Influenza During the Flu Season of 2018–2019: A Longitudinal Study

[Study on clinical symptoms and influencing factors of influenza-associated severe acute respiratory illness in children younger than 5 years old in Suzhou of China, 2011-2017]